Celiac Diseases Drugs Market size is set to grow by USD 1.10 billion from 2024-2028, Higher consumption of gluten-containing food boost the market, Technavio

NEW YORK, Aug. 12, 2024 /PRNewswire/ — The global celiac diseases drugs market size is estimated to grow by USD 1.10 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 21.21%  during the forecast period. Higher consumption of gluten-containing food is driving market growth, with a trend towards inorganic growth strategies. However, poor diagnosis  poses a challenge. Key market players include 9 Meters Biopharma Inc, Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., ImmunogenX Inc., Johnson and Johnson Services Inc., Precigen Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, and Zedira GmbH.

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Market Driver

The Celiac Diseases market is witnessing significant trends with the rise in non-Celiac gluten sensitivity cases. Pharma companies are focusing on developing innovative drug formulation technologies for immunomodulatory therapies to address the unmet medical need of this patient pool. Precision medicine approaches using genetic markers and immune profiles are gaining traction. Symptoms like distension, anorexia, bloating, stomach swelling, dehydration, ion imbalance, dietary deprivation, lack of appetite, and weight loss are common in Celiac Disease. Pharmaceutical treatments are being explored to complement gluten-free diet plans. The market size is substantial due to the large patient pool and high healthcare expenditure from governments and private organizations. Autoimmune disorders linked to Celiac Disease, such as low bone density, neurological disorders, infertility, and gastrointestinal malfunction, add to the disease’s complexity. Drug approval processes are underway for various therapies, including those targeting gluten and gluten-rich food, ready-to-use packaged food, and healthcare systems’ integration. Healthcare professionals play a crucial role in diagnosing and managing Celiac Disease. The market’s growth is driven by the increasing awareness of this genetic disorder and the growing demand for effective treatments. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

• Celiac disease is a complex autoimmune disorder characterized by various symptoms, making it challenging to diagnose at an early stage. Approximately 80% of individuals remain misdiagnosed or undiagnosed, with symptoms appearing at any age, often between 30 and 50. The diagnostic process involves serologic tests, such as tTG-IgA, which require confirmation through intestinal biopsy. Genetic tests, including HLA DQ2 and DQ8 genes, can aid diagnosis but are not definitive. The long diagnostic delay, averaging 11 years, poses a significant market barrier. These challenges may hinder the growth of the celiac disease drugs market during the forecast period.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This celiac diseases drugs market report extensively covers market segmentation by  

1. Therapy 

• 1.1 First line treatment
• 1.2 Second-line treatment

Route Of Administration 

• 2.1 Oral
• 2.2 Parenteral

Geography 

• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 First line treatment-  The celiac diseases market’s first line of treatment primarily focuses on the prevention and management of the disease through a gluten-free diet. This diet is currently the only available option for preventing immune responses that cause various clinical manifestations. The gluten-free diet segment is expected to grow significantly due to the robust pipeline of drugs in the late stages of approval. Currently, there is no approved drug for celiac disease management, making the upcoming approvals a significant development. These approvals will cater to a large patient pool suffering from celiac disease and generate substantial revenue for the market. Government initiatives and tax deductions for gluten-free foods in certain countries further boost market growth. New product launches in the forecast period will have a high impact, contributing to the first entry benefits and changing the market from volume-driven to value-driven. However, economic constraints in low-income regions may limit market penetration and growth. Overall, the first line of treatment segment is poised for considerable growth, driving the market’s expansion during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Learn and explore more about Technavio’s in-depth research reports

The global iron drugs market is experiencing significant growth, driven by increasing cases of anemia and iron deficiency disorders. Key segments include oral and intravenous iron drugs, with rising demand in both developing and developed regions. North America and Europe lead the market, while the Asia-Pacific region shows rapid expansion due to growing healthcare awareness. Major players focus on innovation and strategic partnerships to enhance their market presence. This market is poised for substantial growth, supported by advances in drug formulations and increasing healthcare investments globally.

Research Analysis

Celiac Disease, a genetic disorder, affects the small intestine’s ability to absorb nutrients due to an adverse bodily reaction to gluten, a protein found in wheat, barley, and rye. This autoimmune disorder can lead to various complications, including low bone density, neurological disorders, infertility, and gastrointestinal malfunctions such as diarrhea and abdominal distention. The consumption of gluten-rich food and ready-to-use packaged food can exacerbate symptoms. Healthcare expenditure for Celiac Disease treatment is increasing due to its prevalence and associated complications. Pharmaceutical interventions are crucial for managing symptoms, especially in severe cases. However, a Gluten-free diet remains the primary treatment. Complications like nutrient deficiencies and complications in non-Celiac individuals are also being addressed through drug formulation technology and healthcare systems’ precision medicine approaches.

Market Research Overview

Celiac Disease, an autoimmune disorder, is caused by a bodily reaction to gluten found in wheat, barley, and rye. This genetic disorder affects the small intestine, leading to gastrointestinal malfunction, resulting in symptoms like diarrhea, abdominal distention, loss of lymphocytes, and nutrient malabsorption. Complications include low bone density, neurological disorders, infertility, and even misdiagnosis as bowel disorders. Gluten-rich food, ready-to-use packaged food, and healthcare expenditure are significant factors driving the need for celiac disease drugs. Governments and private organizations are investing in drug approval and clinical trials for celiac drug innovation. Pharmaceutical companies are developing tablets and immunomodulatory therapies using drug formulation technology and precision medicine.

Table of Contents:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation

• Therapy
• First Line Treatment
• Second-line Treatment
• Route Of Administration
• Oral
• Parenteral
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape

8 Geographic Landscape

9 Drivers, Challenges, and Trends

10 Company Landscape

11 Company Analysis

12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/

SOURCE Technavio

Go to Source